Comments on the MRC/BHF Heart Protection Study - Authors' reply

Comments on the MRC/BHF Heart Protection Study - Authors' reply

Detalhes bibliográficos
Principais autores:	Collins, R, Armitage, J, Parish, S, Sleight, P, Peto, R, Col, M
Formato:	Journal article
Publicado em:	2003

Registros relacionados

MRC/BHF Heart Protection Study - Reply
por: Collins, R, et al.
Publicado em: (2002)

The MRC/BHF Heart Protection Study: preliminary results.
por: Collins, R, et al.
Publicado em: (2002)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
por: Collins, R, et al.
Publicado em: (2002)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
por: Collins, R, et al.
Publicado em: (2003)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
por: Parish, S, et al.
Publicado em: (2012)

MRC/BHF Heart Protection Study.
por: Vaughan, C, et al.
Publicado em: (2002)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
por: Emberson, J, et al.
Publicado em: (2005)

Heart Protection Study - Reply
por: Collins, R, et al.
Publicado em: (2003)

New analyses of Heart Protection Study - Reply
por: Collins, R, et al.
Publicado em: (2004)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
por: Emberson, J, et al.
Publicado em: (2005)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
por: Bulbulia, R, et al.
Publicado em: (2007)

Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.
por: Armitage, J, et al.
Publicado em: (2000)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
por: Emberson, JR, et al.
Publicado em: (2007)

C-reactive protein in the Heart Protection Study - Authors' reply
por: Emberson, J, et al.
Publicado em: (2011)

Randomized trial of cholesterol-lowering and antioxidant vitamins in 5,000 women at high-risk of coronary heart disease
por: Collins, R, et al.
Publicado em: (2002)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
por: Heart Protection Study Collaborative Group
Publicado em: (2002)

AFTER ISIS-3 - REPLY
por: Collins, R, et al.
Publicado em: (1992)

C-reactive protein in the Heart Protection Study Reply
por: Emberson, J, et al.
Publicado em: (2011)

Randomized trial of cholesterol-lowering and antioxidant vitamins in 7,000 high-risk individuals with LDL cholesterol below 120 mg/dl
por: Collins, R, et al.
Publicado em: (2002)

Effects of cholesterol-lowering therapy and antioxidant vitamin supplementation on the risk of stroke
por: Collins, R, et al.
Publicado em: (2002)

Randomized trial of cholesterol-lowering, and of antioxidant vitamins, in 6,000 people with diabetes mellitus
por: Collins, R, et al.
Publicado em: (2002)

The authors reply
por: Collins, R, et al.
Publicado em: (2009)

ISIS-4 - REPLY
por: Collins, R, et al.
Publicado em: (1995)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
por: Collins, R, et al.
Publicado em: (2004)

Author reply to comments
por: Ashu Seith Bhalla, et al.
Publicado em: (2015-10-01)

Author reply to comments
por: Ashu Seith Bhalla, et al.
Publicado em: (2015-01-01)

Authors' reply [5]
por: Chen, Z, et al.
Publicado em: (2006)

The authors reply
por: Jha, P, et al.
Publicado em: (2008)

MRC BHFHeart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience
por: Meade, T, et al.
Publicado em: (1999)

Lessons from the controversy over statins - Authors' reply.
por: Armitage, J, et al.
Publicado em: (2016)

ISIS-3 - REPLY
por: Collins, R, et al.
Publicado em: (1991)

Safety and efficacy of statins - Authors' reply
por: Collins, R, et al.
Publicado em: (2017)

COMMIT/CCS-2 studies - Authors' reply
por: Chen, Z, et al.
Publicado em: (2006)

Authors' reply
por: Peto, R, et al.
Publicado em: (2013)

In search of genetic precision - Reply
por: Keaveny, B, et al.
Publicado em: (2003)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
por: Hopewell, J, et al.
Publicado em: (2011)

ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.
por: Collins, R, et al.
Publicado em: (1993)

LOW CHOLESTEROL AND CORONARY HEART-DISEASE - REPLY
por: Chen, Z, et al.
Publicado em: (1991)

Assessing the impact sensitivity of explosives using the BHF-12A equipment
por: Rădeanu Cristian, et al.
Publicado em: (2020-01-01)

Did alcohol protect against death from breast cancer in Russia? Authors' reply
por: Zaridze, D, et al.
Publicado em: (2009)